Nielsen William Herrik, Gustafsson Finn
Department of Cardiology, Copenhagen University Hospital, Rigshospitalet Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen Copenhagen, Denmark.
Card Fail Rev. 2024 Jul 18;10:e08. doi: 10.15420/cfr.2023.26. eCollection 2024.
Iron deficiency is a common and independent predictor of adverse outcomes in patients with heart failure. The implications of iron deficiency in patients implanted with a left ventricular assist device (LVAD) are less established. This review recaps data on the prevalence, characteristics and impact of Iron deficiency in the LVAD population. A systematic search yielded eight studies involving 517 LVAD patients, with iron deficiency prevalence ranging from 40% to 82%. IV iron repletion was not associated with adverse events and effectively resolved iron deficiency in most patients. However, the effects of iron deficiency and iron repletion on post-implant survival and exercise capacity remain unknown. Although iron deficiency is highly prevalent in LVAD patients, its true prevalence and adverse effects may be misestimated due to inexact diagnostic criteria. Future randomised controlled trials on IV iron treatment in LVAD patients are warranted to clarify the significance of this common comorbidity.
缺铁是心力衰竭患者不良预后的常见且独立的预测因素。缺铁对植入左心室辅助装置(LVAD)患者的影响尚不明确。本综述总结了LVAD人群中铁缺乏的患病率、特征及影响的数据。系统检索得到八项研究,涉及517例LVAD患者,缺铁患病率在40%至82%之间。静脉补铁与不良事件无关,且在大多数患者中有效纠正了缺铁情况。然而,缺铁及补铁对植入后生存和运动能力的影响仍不清楚。尽管缺铁在LVAD患者中非常普遍,但由于诊断标准不精确,其真实患病率和不良影响可能被高估。未来有必要对LVAD患者进行静脉铁治疗的随机对照试验,以阐明这种常见合并症的意义。